Track Zynex, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Zynex, Inc. ZYXI Open Zynex, Inc. in new tab

0.0550 USD
P/E
57.79
EPS
-2.41
P/B
-0.22
ROE
-168.22
Beta
1.00
Zynex, Inc. logo

Zynex, Inc.

🧾 Earnings Recap – Q3 2025

Zynex, Inc. reported a challenging third quarter for 2025 marked by significant management changes and strategic pivots aimed at addressing compliance issues and improving financial stability.

  • Newly appointed management is focused on compliance, governance, and strategic marketing to turn the company around.
  • A proactive resupply order fulfillment policy has led to increased patient engagement and improved customer experience.
  • The company faces liquidity challenges with $60 million in convertible senior notes maturing in May 2026, necessitating urgent capital raising efforts.
  • Initial signs of stabilization in customer order volumes have been observed despite a reduced sales force, supported by revamped commission plans and focused sales strategies.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateApril 27, 2026
P/E57.79
EPS-2.41
Book Value-1.34
Price to Book-0.22
Debt/Equity5746.23
% Insiders48.163%
Growth
Revenue Growth-0.73%
Earnings Growth-0.30%
Estimates
Forward P/E0.26
Forward EPS0.48

DCF Valuation

Tweak assumptions to recompute fair value for Zynex, Inc. (ZYXI)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Zynex, Inc. Logo Zynex, Inc. Analysis (ZYXI)

United States Health Care Official Website Stock

Is Zynex, Inc. a good investment? Zynex, Inc. (ZYXI) is currently trading at 0.0550 USD.

In terms of valuation, the stock trades at a P/E ratio of 57.79. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Zynex, Inc. is expected to release its next earnings report on April 27, 2026. The market consensus estimate for Forward EPS is 0.48.

Investor FAQ

Does Zynex, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Zynex, Inc.?

Zynex, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 27, 2026. The company currently has a trailing EPS of -2.41.

Company Profile

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. On December 15, 2025, Zynex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Exchange Ticker
NCM (Australia) ZYXI
Historical Dividends
Year Total Dividends
2022 0.09 USD
2019 0.06 USD
2014 0.14 USD

Yearly aggregated dividends

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Jan. 5, 2022 1.100000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion